All Stories

  1. Primary pulmonary chondrosarcoma: clinical case and review of the literature

    Article • Therapeutic Advances in Respiratory Disease, December 2025, SAGE Publications

    Anastasia Papaporfyriou

  2. Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review

    Article • Current Oncology, October 2024, MDPI AG

    Anastasia Papaporfyriou

  3. The Perioperative Use of Levosimendan as a Means of Optimizing the Surgical Outcome in Patients with Severe Heart Insufficiency Undergoing Cardiac Surgery

    Article • Journal of Cardiovascular Development and Disease, August 2023, MDPI AG

    Anastasia Papaporfyriou

  4. Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy

    Article • Life, May 2023, MDPI AG

    Dr Konstantinos Panagiotis Bartziokas, Anastasia Papaporfyriou

  5. Global initiative for chronic obstructive lung disease (GOLD) recommendations: strengths and concerns for future needs

    Article • Postgraduate Medicine, October 2022, Taylor & Francis

    Dr Konstantinos Panagiotis Bartziokas, Anastasia Papaporfyriou

  6. Lung Metastatectomy: Can Laser-Assisted Surgery Make a Difference?

    Article • September 2022, MDPI AG

    Anastasia Papaporfyriou

  7. Can Chest Ultrasound Replace Chest X-ray in Thoracic Surgery?

    Article • Tomography, August 2022, MDPI AG

    Anastasia Papaporfyriou

  8. RELIght: A two‐year REal‐LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response

    Article • Allergy, May 2022, Wiley

    Anastasia Papaporfyriou

  9. Blood eosinophils in COPD: friend or foe?

    Article • Expert Review of Respiratory Medicine, December 2021, Taylor & Francis

    Anastasia Papaporfyriou

  10. Updated simplified approach of pharmacological treatment of stable COPD: Do common co-morbidities have a role?

    Article • Postgraduate Medicine, August 2021, Taylor & Francis

    Anastasia Papaporfyriou

  11. Depression Levels Influence the Rate of Asthma Exacerbations in Females

    Article • Journal of Personalized Medicine, June 2021, MDPI AG

    Anastasia Papaporfyriou

  12. Device use errors among patients with asthma and COPD and the role of training: a real-life study

    Article • Postgraduate Medicine, March 2021, Taylor & Francis

    Dr Konstantinos Panagiotis Bartziokas, Anastasia Papaporfyriou

  13. Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature

    Article • European Respiratory Review, January 2021, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  14. PROMS and FEV1 as predictors of AECOPD

    Article • September 2020, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  15. Prevalence, distribution and clinical significance of joints, muscles and bones in sarcoidosis: an 18F-FDG-PET/CT study

    Article • Expert Review of Respiratory Medicine, June 2020, Taylor & Francis

    Anastasia Papaporfyriou

  16. Sirtuin 1: Endocan and Sestrin 2 in Different Biological Samples in Patients with Asthma. Does Severity Make the Difference?

    Article • Journal of Clinical Medicine, February 2020, MDPI AG

    Anastasia Papaporfyriou

  17. Pharmacological treatment of stable COPD: need for a simplified approach

    Article • Postgraduate Medicine, January 2020, Taylor & Francis

    Anastasia Papaporfyriou

  18. Asthma‐chronic obstructive pulmonary disease overlap: Diagnostic stability and inflammatory characteristics

    Article • Allergy, May 2019, Wiley

    Anastasia Papaporfyriou

  19. Inflammatory profile in optimally treated patients with adult versus early-onset asthma

    Article • Postgraduate Medicine, March 2019, Taylor & Francis

    Nickolaos Koulouris, Professor Petros A Bakakos, Anastasia Papaporfyriou

  20. TERT/TERC mutations in a Greek cohort of suspected genetic pulmonary fibrosis patients

    Article • September 2018, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  21. Mycophenalate Mofetil as a corticosteroid- sparing agent in patients with sarcoidosis.

    Article • September 2018, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  22. The effects of pulmonary rehabilitation in patients with Combined Pulmonary Fibrosis and Emphysema (CPFE)

    Article • September 2018, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  23. Late onset asthma: A distinct phenotype

    Article • September 2018, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  24. Serum Surfactant Protein Levels in Patients Admitted to the Hospital with Acute COPD Exacerbation

    Article • Lung, February 2018, Springer Science + Business Media

    Dr Konstantinos Panagiotis Bartziokas, Anastasia Papaporfyriou

  25. Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, November 2017, Taylor & Francis

    Anastasia Papaporfyriou

  26. Decreased Serum Sirtuin-1 in COPD

    Article • CHEST Journal, August 2017, Elsevier

    Anastasia Papaporfyriou

  27. Serum periostin in patients hospitalized for COPD exacerbations

    Article • Cytokine, May 2017, Elsevier

    Dr Konstantinos Panagiotis Bartziokas, Anastasia Papaporfyriou

  28. Activin A and follistatin in patients with asthma. Does severity make the difference?

    Article • Respirology, November 2016, Wiley

    Anastasia Papaporfyriou

  29. Sputum interleukin‐13 as a biomarker for the evaluation of asthma control

    Article • Clinical & Experimental Allergy, October 2016, Wiley

    Anastasia Papaporfyriou

  30. Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation

    Article • September 2016, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  31. Clinical, functional and inflammatory characteristics in patients with paucigranulocytic asthma

    Article • September 2016, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  32. Predictors of future exacerbation risk in patients with asthma

    Article • Postgraduate Medicine, August 2016, Taylor & Francis

    Anastasia Papaporfyriou

  33. Sputum interleukin-13 as a biomarker for the evaluation of asthma control

    Article • Clinical & Experimental Allergy, May 2016, Wiley

    Professor Petros A Bakakos, Anastasia Papaporfyriou

  34. Persistent airflow obstruction in patients with asthma: Characteristics of a distinct clinical phenotype

    Article • Respiratory Medicine, November 2015, Elsevier

    Anastasia Papaporfyriou

  35. Predictors of exacerbations in asthma

    Article • September 2015, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  36. Activin-A BAL levels and Immunochemistry for activin A receptors in patients with asthma

    Article • September 2015, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  37. Periostin as a biomarker in patients with asthma: Associations with eosinophilia and Th2 response

    Article • September 2015, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  38. Serum periostin in patients hospitalized for COPD exacerbations

    Article • September 2015, European Respiratory Society (ERS)

    Anastasia Papaporfyriou

  39. Pulmonary alveolar proteinosis: time to shift?

    Article • Expert Review of Respiratory Medicine, April 2015, Taylor & Francis

    Professor Panagiotis Tsirigotis , Anastasia Papaporfyriou

  40. Sputum interleukin (IL)-13 as a biomarker for the evaluation of asthma control

    Article • Clinical and Translational Allergy, March 2015, Springer Science + Business Media

    Anastasia Papaporfyriou

  41. Sputum and BAL Clara cell secretory protein and surfactant protein D levels in asthma

    Article • Allergy, March 2015, Wiley

    Professor Petros A Bakakos, Anastasia Papaporfyriou

  42. Increased Levels of Osteopontin in Sputum Supernatant in Patients With COPD

    Article • CHEST Journal, October 2014, Elsevier

    Professor Petros A Bakakos, Anastasia Papaporfyriou

  43. Long-Term Inhaled Granulocyte Macrophage–Colony-Stimulating Factor in Autoimmune Pulmonary Alveolar Proteinosis: Effectiveness, Safety, and Lowest Effective Dose

    Article • Clinical Drug Investigation, June 2014, Springer Science + Business Media

    Professor Panagiotis Tsirigotis , Anastasia Papaporfyriou

  44. Levels of prostaglandin E2 and Cysteinyl‐leukotrienes in sputum supernatant of patients with asthma: the effect of smoking

    Article • Clinical & Experimental Allergy, May 2013, Wiley

    Anastasia Papaporfyriou

  45. Noninvasive evaluation of airway inflammation in patients with severe asthma

    Article • Annals of Allergy Asthma & Immunology, May 2013, Elsevier

    Professor Petros A Bakakos, Anastasia Papaporfyriou